Individualized target therapy of malignant lymphomas: an outlook.
Hodgkin and non-Hodgkin lymphomas represent clonal malignant expansions of B or T cells that are at various stages of maturation. As our understanding of the immunophenotype, cytogenetics and molecular biology of the lymphomas broadened, treatment of these neoplasms is evolving to include targeted therapies directed against tumour-characteristic molecules and specific signalling pathways critical to lymphomagenesis.
Anagnostopoulos
Ioannis
I
Institut für Pathologie, Charité Campus Benjamin Franklin, Berlin, Germany.
D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis / Q000378:metabolism; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D016328:NF-kappa B / Q000032:analysis / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000378:metabolism; D009857:Oncogenes; D011505:Protein-Tyrosine Kinases / Q000032:analysis / Q000378:metabolism; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000032:analysis / Q000378:metabolism
D017730:Ki-1 Antigen; D016328:NF-kappa B; D015514:Oncogene Proteins, Fusion; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase